TransMedics Group, Inc.
TMDX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $442 | $242 | $93 | $30 |
| % Growth | 82.7% | 158.5% | 208.8% | – |
| Cost of Goods Sold | $179 | $88 | $28 | $9 |
| Gross Profit | $262 | $154 | $65 | $21 |
| % Margin | 59.4% | 63.8% | 69.8% | 69.9% |
| R&D Expenses | $56 | $63 | $27 | $22 |
| G&A Expenses | $169 | $120 | $52 | $38 |
| SG&A Expenses | $169 | $120 | $70 | $38 |
| Sales & Mktg Exp. | $0 | $0 | $18 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $225 | $183 | $97 | $61 |
| Operating Income | $37 | -$29 | -$31 | -$39 |
| % Margin | 8.5% | -11.9% | -33.6% | -130.3% |
| Other Income/Exp. Net | -$2 | $2 | -$5 | -$5 |
| Pre-Tax Income | $36 | -$27 | -$36 | -$44 |
| Tax Expense | $0 | -$2 | $0 | $0 |
| Net Income | $35 | -$25 | -$36 | -$44 |
| % Margin | 8% | -10.4% | -38.8% | -146.1% |
| EPS | 1.07 | -0.77 | -1.23 | -1.6 |
| % Growth | 239% | 37.4% | 23.1% | – |
| EPS Diluted | 1.01 | -0.77 | -1.23 | -1.6 |
| Weighted Avg Shares Out | 33 | 33 | 30 | 28 |
| Weighted Avg Shares Out Dil | 35 | 33 | 30 | 28 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $13 | $1 | $0 |
| Interest Expense | $14 | $11 | $4 | $4 |
| Depreciation & Amortization | $20 | $8 | $3 | $2 |
| EBITDA | $70 | -$8 | -$29 | -$38 |
| % Margin | 15.8% | -3.2% | -31% | -127.2% |